Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

925 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protease inhibitor therapy for hepatitis C virus-infection.
de Leuw P, Stephan C. de Leuw P, et al. Among authors: stephan c. Expert Opin Pharmacother. 2018 Apr;19(6):577-587. doi: 10.1080/14656566.2018.1454428. Epub 2018 Mar 29. Expert Opin Pharmacother. 2018. PMID: 29595065 Review.
The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
Bickel M, Rickerts V, Stephan C, Jacobi V, Rottmann C, Dauer B, Carlebach A, Thalhammer A, Miller V, Staszweski S. Bickel M, et al. Among authors: stephan c. HIV Med. 2005 May;6(3):179-84. doi: 10.1111/j.1468-1293.2005.00286.x. HIV Med. 2005. PMID: 15876284 Free article. Clinical Trial.
Similar long-term efficacy of dual therapy containing raltegravir and a boosted protease inhibitor versus standard triple therapies in pretreated HIV-1-infected patients in a retrospective, real-life cohort of 14 years.
Krznaric I, Bickel M, Carganico A, De Leuw P, Haberl A, Knecht G, Koegl C, Lauscher P, Schüttfort G, Stephan C, Wolf E, Wolf T. Krznaric I, et al. Among authors: stephan c. HIV Med. 2018 Oct;19(9):662-667. doi: 10.1111/hiv.12636. Epub 2018 Jul 3. HIV Med. 2018. PMID: 29971922 Free article.
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
Mocroft A, Neesgard B, Zangerle R, Rieger A, Castagna A, Spagnuolo V, Antinori A, Lampe FC, Youle M, Vehreschild JJ, Mussini C, Borghi V, Begovac J, Duvivier C, Gunthard HF, Rauch A, Tiraboschi J, Chkhartishvili N, Bolokadze N, Wit F, Wasmuth JC, De Wit S, Necsoi C, Pradier C, Svedhem V, Stephan C, Petoumenos K, Garges H, Rogatto F, Peters L, Ryom L; RESPOND study group. Mocroft A, et al. Among authors: stephan c. HIV Med. 2020 Oct;21(9):599-606. doi: 10.1111/hiv.12888. Epub 2020 Jun 26. HIV Med. 2020. PMID: 32588958 Free article.
Antiretroviral treatment outcomes among late HIV presenters initiating treatment with integrase inhibitors or protease inhibitors.
Schuettfort G, Boekenkamp L, Cabello A, Cotter AG, De Leuw P, Doctor J, Górgolas M, Hamzah L, Herrmann E, Kann G, Khaykin P, Mallon PW, Mena A, Del Palacio Tamarit M, Sabin CA, Stephan C, Wolf T, Haberl AE. Schuettfort G, et al. Among authors: stephan c. HIV Med. 2021 Jan;22(1):47-53. doi: 10.1111/hiv.12962. Epub 2020 Oct 13. HIV Med. 2021. PMID: 33047484 Free article.
925 results